← brief for 2026-09-03 · Slowing decline

Sodium-Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage-Dependent Systemic-Retinal Responsiveness.

Key takeaways

SGLT2 inhibitors are a main drug class for slowing kidney decline, and this review asked what they do to diabetic macular oedema, swelling at the back of the eye that blurs vision. The authors gathered real world data, trial results, and lab work, and asked whether the effect depends on how far the eye disease has progressed. The evidence is mixed and mostly observational, so it shows links, not proof of cause. It does not change how these drugs are used for kidney disease.

Who did this work

Ishibashi R · Hirayama K · Sakai T · Tatsumi T · Takatsuna Y · Baba T · Koshizaka M · Yokote K

Source

Article · PubMed, the drug frontier · 2026 Sep 2
https://pubmed.ncbi.nlm.nih.gov/42686660/